Antimucin 17 antibodies, their conjugates and their uses

AR135370A1Pending Publication Date: 2026-09-02HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO LTD

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: ARP20250100557
Authority / Receiving Office: AR · AR
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2025-02-26
Filing Date: 2025-02-28
Publication Date: 2026-09-02

Application Information

Patent Timeline

26 Feb 2025

Priority

28 Feb 2025

Application

ARP20250100557

02 Sep 2026

Publication

AR135370A1

IPC: C07K16/00; C07K19/00; A61K39/395; A61P35/00; C12N15/13; C12N5/10; G01N33/574; G01N33/68

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Need to check novelty before this filing date? Find Prior Art

No text content released.

Claims

The present invention relates to an antibody that specifically binds to the target mucin 17 (MUC17), an antibody-drug conjugate and methods for its use, as well as compositions and a detection system containing the molecules. The anti-MUC17 antibody, its conjugate, or its compositions can be used as a standalone therapy, such as in the treatment of cancer / tumors, or in combination with other therapies or other anticancer agents.